Eli Lil­ly ax­es an ear­ly-stage PD-L1/TIM-3 bis­pe­cif­ic pro­gram in lat­est pipeline cleanup

Three months af­ter Eli Lil­ly $LLY fol­lowed up on its move to high­light a se­lect group of can­cer drugs in the pipeline with the elim­i­na­tion of 2 mid-stage on­col­o­gy pro­grams, the phar­ma gi­ant is bring­ing out the ax to lop off an ear­ly-stage PD-L1/TIM-3 bis­pe­cif­ic.

Its Q2 up­date to­day notes that the bis­pe­cif­ic is be­ing swept out along­side an an­ti-in­flam­ma­to­ry pro­gram for IL-23/CGRP in im­munol­o­gy.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER